CONTEXT
Sepsis is one of the complications that can occur after cardiac surgery with extracorporeal circulation. This generalized inflammatory immune response is associated to a very poor clinical prognosis with a mortality rate of about 30%, hence the challenge of early detection. However, there are currently no consensual biological tests for the early screening of patients at risk of sepsis after cardiac surgery.
DESCRIPTION
The present invention relates to a method for predicting the risk of sepsis for a patient undergoing surgery, comprising the step of measuring preoperative cholesterolemia of said patient, wherein low preoperative cholesterolemia is associated with an increased risk of sepsis. It also allows to more precisely predict the postoperative risk by measuring blood levels of interleukin 8 (IL-8) and/or procalcitonin (PCT) in the patient, wherein an increase in IL-8 and/or PCT levels within 6 hours after the surgical operation is associated with sepsis onset.
COMPETITIVE ADVANTAGES
MARKETS & APPLICATIONS
Health - prevention/diagnosis:
Pre- and postoperative follow-up on the risks of developing sepsis
DEVELOPMENT STAGE
Prospective observational study in 217 patients who underwent cardiac surgery with extracorporeal circulation: demonstrating that preoperative low cholesterol levels are associated with an increased risk of sepsis (publication: Lagrost, Crit Care Med 2014)
RESEARCH TEAM
Laboratory Lipids, Nutrition, Cancer University of Burgundy - INSERM
INTELLECTUAL PROPERTY
European patent issued in France, UK and Germany (filed on October 18, 2013)
TARGET PARTNERSHIP
Patent licensing
CONTACT
Daniel KIRCHHERR
Business Development Manager
+33 (0)7 76 16 66 90
daniel.kirchherr@sayens.fr